"The origin of firstinclass drugs: innovation versus clinical benefit"
The last thing to say here, payers are Scared and rightly scared of how much it will cost them in the short term if they do start covering these drugs
The primary safety concern with compounded lipotropic preparations is variability in formulation quality and sterility , as compounding pharmacies operate under different regulatory standards than pharmaceutical manufacturers
Eli Lilly developed tirzepatide for type 2 diabetes (Mounjaro, FDA-approved 2022) and later for chronic weight management (Zepbound, 2023)
It is important to note that while GLP-1RAs have demonstrated CV safety, not all result in an actual reduction in CV adverse events, such as exenatide QW and lixisenatide, both of which were reported to be non-inferior to placebo for MACE [22, 23]
This guide provides comprehensive information on dosing protocols, common experiences during the first weeks, expected clinical benefits, and practical strategies for successful long-term therapy